SCHEMBL6538477

SCHEMBL6538477

CC(C)n1nc(-c2cc(-c3ccccc3)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 5/20 0.38
PDE1A P54750 1/20 0.38
PDE1B Q01064 1/20 0.38
PDE1C Q14123 1/20 0.38
ADORA1 P30542 3/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
SRC P12931 5/20 0.36
ABL1 P00519 4/20 0.36
PIK3CD O00329 3/20 0.36
PIK3CA P42336 3/20 0.36
PIK3CB P42338 3/20 0.36
PIK3CG P48736 3/20 0.36
PRKDC P78527 3/20 0.36
RET P07949 2/20 0.36
P2RY6 Q15077 1/20 0.36
SMARCA2 P51531 1/20 0.35
SMARCA4 P51532 1/20 0.35
PBRM1 Q86U86 1/20 0.35
BMPR1B O00238 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538926 0.88 POLB (0.39) ADORA2APDE1APDE1BPDE1CADORA1
SCHEMBL6539119 0.88 ADORA2A (0.36) ADORA2APDE1APDE1BPDE1CTP53
SCHEMBL6539038 0.88 ADORA2A (0.36) ADORA2APDE1APDE1BPDE1CTP53
SCHEMBL6538453 0.87 RXFP1 (0.38) TP53P2RY6
SCHEMBL6538765 0.86 MET (0.40) ADORA2APDE1APDE1BPDE1CADORA1
SCHEMBL6538908 0.86 SRC (0.35) ADORA2APDE1APDE1BPDE1CPOLB
SCHEMBL6538474 0.85 RET (0.41) ADORA2APDE1APDE1BPDE1CADORA1
SCHEMBL6538517 0.85 AKT1 (0.39) ADORA2AADORA1SRCABL1PIK3CD
SCHEMBL6538806 0.85 PDE1A (0.42) ADORA2APDE1APDE1BPDE1CADORA1
SCHEMBL6539194 0.85 RET (0.37) ADORA2APDE1APDE1BPDE1CADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 ADORA2A 2/4885PDE1A 391/4885PDE1B 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.